Mirum and Kodiak Sciences share study results
Mirum and Kodiak Sciences share study results
Updated at: September 28, 2026 at 01:45 AM
On September 28, 2026, the biotechnology sector saw significant updates from two major companies: Mirum Pharmaceuticals and Kodiak Sciences.
While their announcements occurred on the same day, it is crucial to note that they are not collaborating.
These are entirely separate corporate updates involving distinct clinical trials and therapeutic focuses.
Mirum Pharmaceuticals hosted an investor call to share positive topline results from their Phase 3 AZURE-1 study of brelovitug, which targets chronic hepatitis delta virus (HDV).
Meanwhile, Kodiak Sciences held a webcast to report findings from their DAYBREAK pivotal Phase 3 study.
By looking at these companies, we see a clear divide: Mirum remains focused on rare diseases, while Kodiak Sciences concentrates on retinal health.
Understanding that these are independent milestones helps investors and researchers avoid confusion between different drugs, study goals, and market strategies.
